These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 22447530)

  • 1. Gender differences in pharmacokinetics of lumefantrine and its metabolite desbutyl-lumefantrine in rats.
    Wahajuddin ; Singh SP; Jain GK
    Biopharm Drug Dispos; 2012 May; 33(4):229-34. PubMed ID: 22447530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats.
    Wahajuddin ; Singh SP; Raju KS; Nafis A; Puri SK; Jain GK
    Malar J; 2011 Oct; 10():293. PubMed ID: 21985153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How much fat is necessary to optimize lumefantrine oral bioavailability?
    Ashley EA; Stepniewska K; Lindegårdh N; Annerberg A; Kham A; Brockman A; Singhasivanon P; White NJ; Nosten F
    Trop Med Int Health; 2007 Feb; 12(2):195-200. PubMed ID: 17300625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria.
    Ashley EA; Stepniewska K; Lindegårdh N; McGready R; Annerberg A; Hutagalung R; Singtoroj T; Hla G; Brockman A; Proux S; Wilahphaingern J; Singhasivanon P; White NJ; Nosten F
    Trop Med Int Health; 2007 Feb; 12(2):201-8. PubMed ID: 17300626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparable lumefantrine oral bioavailability when co-administered with oil-fortified maize porridge or milk in healthy volunteers.
    Mwebaza N; Jerling M; Gustafsson LL; Obua C; Waako P; Mahindi M; Ntale M; Beck O; Hellgren U
    Basic Clin Pharmacol Toxicol; 2013 Jul; 113(1):66-72. PubMed ID: 23480875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-situ single pass intestinal permeability and pharmacokinetic study of developed Lumefantrine loaded solid lipid nanoparticles.
    Garg A; Bhalala K; Tomar DS; Wahajuddin
    Int J Pharm; 2017 Jan; 516(1-2):120-130. PubMed ID: 27989820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.
    Borrmann S; Sallas WM; Machevo S; González R; Björkman A; Mårtensson A; Hamel M; Juma E; Peshu J; Ogutu B; Djimdé A; D'Alessandro U; Marrast AC; Lefèvre G; Kern SE
    Trop Med Int Health; 2010 Apr; 15(4):434-41. PubMed ID: 20180933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology.
    du Plessis LH; Govender K; Denti P; Wiesner L
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):68-77. PubMed ID: 26478276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous quantification of proposed anti-malarial combination comprising of lumefantrine and CDRI 97-78 in rat plasma using the HPLC-ESI-MS/MS method: application to drug interaction study.
    Wahajuddin M; Singh SP; Taneja I; Raju KS; Gayen JR; Siddiqui HH; Singh SK
    Malar J; 2015 Apr; 14():172. PubMed ID: 25895956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques.
    Ramanathan-Girish S; Catz P; Creek MR; Wu B; Thomas D; Krogstad DJ; De D; Mirsalis JC; Green CE
    Int J Toxicol; 2004; 23(3):179-89. PubMed ID: 15204721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of a bioanalytical method using automated solid-phase extraction and LC-UV for the simultaneous determination of lumefantrine and its desbutyl metabolite in plasma.
    Lindegårdh N; Annerberg A; Blessborn D; Bergqvist Y; Day N; White NJ
    J Pharm Biomed Anal; 2005 Apr; 37(5):1081-8. PubMed ID: 15862688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of pharmacokinetic compatibility of short acting CDRI candidate trioxane derivative, 99-411, with long acting prescription antimalarials, lumefantrine and piperaquine.
    Taneja I; Raju KS; Singh SP; Wahajuddin M
    Sci Rep; 2015 Nov; 5():17264. PubMed ID: 26602250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved pharmacokinetic and pharmacodynamic attributes of artemether-lumefantrine-loaded solid SMEDDS for oral administration.
    Bhandari S; Bhandari V; Sood J; Jaswal S; Rana V; Bedi N; Sehgal R; Tiwary AK
    J Pharm Pharmacol; 2017 Nov; 69(11):1437-1446. PubMed ID: 28809448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of lumefantrine in rat plasma by liquid-liquid extraction using LC-MS/MS with electrospray ionization: assay development, validation and application to a pharmacokinetic study.
    Wahajuddin ; Singh SP; Jain GK
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Apr; 877(11-12):1133-9. PubMed ID: 19285925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical pharmacokinetics, dose proportionality, gender difference and protein binding study of 16-dehydropregnenolone, an antihyperlipidemic agent, in rats.
    Suryawanshi S; Wahajuddin ; Gupta RC; Singh SK
    J Pharm Pharmacol; 2011 Jan; 63(1):41-8. PubMed ID: 21155814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of the functional role of P-glycoprotein in limiting the oral bioavailability of lumefantrine.
    Wahajuddin ; Raju KS; Singh SP; Taneja I
    Antimicrob Agents Chemother; 2014; 58(1):489-94. PubMed ID: 24189249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Method development and validation for simultaneous determination of lumefantrine and its major metabolite, desbutyl lumefantrine in human plasma using RP-HPLC/UV detection.
    Khuda F; Iqbal Z; Shah Y; Ahmmad L; Nasir F; Khan AZ; Amanullah ; Shahbaz N
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 944():114-22. PubMed ID: 24316521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
    Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda.
    Checchi F; Piola P; Fogg C; Bajunirwe F; Biraro S; Grandesso F; Ruzagira E; Babigumira J; Kigozi I; Kiguli J; Kyomuhendo J; Ferradini L; Taylor WR; Guthmann JP
    Malar J; 2006 Jul; 5():59. PubMed ID: 16854236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
    Chan S; Edwards SR; Wyse BD; Smith MT
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):295-302. PubMed ID: 17973932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.